Actively Recruiting
Randomized Double-Blind Trial of MB-1 Dietary Supplement Versus Placebo for Metabolic Health in Overweight and Obese Adults
Led by Arrae · Updated on 2026-09-30
120
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of MB-1, a dietary supplement, on metabolic health in adults who are overweight or obese. The study focuses on changes in body weight over 84 days, comparing MB-1 to a placebo. The main goal is to understand how MB-1 influences weight and other health markers in this population. Participants will take two capsules of either MB-1 or a placebo every morning with a meal from Day 1 until just before their final study visit at Day 84. MB-1 contains extracts from African mango seed, Cissus leaf, Grains of Paradise, Bifidobacterium Lactis B420, green tea extract, vitamin B6, and chromium picolinate. The placebo contains white rice flour. The study is randomized and double-blind, meaning neither the participants nor the researchers know who receives MB-1 or placebo. During the study, participants will have their body measurements, blood pressure, and heart rate monitored. They will complete questionnaires about appetite and satiety and undergo a DEXA scan to assess body composition. Researchers will measure changes in body weight, waist and hip circumference, fat and muscle mass, blood glucose, lipid profiles, appetite, satiety, cravings, and energy levels. The trial lasts 84 days, with assessments at regular intervals to track these outcomes.
CONDITIONS
Brief Title
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
Research Team
E
Erin Lewis, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here